{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:51:28Z","timestamp":1791273088584,"version":"4.1.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA274499"],"award-info":[{"award-number":["U54CA274499"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA44579"],"award-info":[{"award-number":["P30CA44579"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA274499"],"award-info":[{"award-number":["U54CA274499"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA274499"],"award-info":[{"award-number":["U54CA274499"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA44579"],"award-info":[{"award-number":["P30CA44579"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,10,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In RAS-mutant tumours, ERK phosphorylates the mitochondrial fission GTPase DRP1 to promote mitochondrial fission. DRP1 activity is tumour-promoting in pancreatic and other RAS-driven cancers, but its role in therapeutic resistance is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We developed a panel of patient-derived pancreatic cancer cell lines resistant to the MEK inhibitor trametinib. We used immunofluorescence imaging, in vitro growth assays and orthotopic xenografts to determine the role of DRP1 in trametinib resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We find that trametinib-resistant cells exhibit increased expression and phosphorylation of DRP1 compared to sensitive counterparts. Quantitative analysis of mitochondrial structure reveals that mitochondria in resistant cells are morphologically distinct and relatively smaller than sensitive cells treated with trametinib. Genetic and pharmacological inhibition of both c-Myc and CDK6 are sufficient to block DRP1 phosphorylation in resistant cells, suggesting that activation of a c-Myc-CDK6 signalling axis drives reactivation of mitochondrial fission in the absence of MAPK signalling. Importantly, deletion of DRP1 leads to either growth inhibition or re-sensitisation to trametinib in resistant lines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings suggest DRP1 contributes to drug resistance, and that inhibition of mitochondrial fission might be a promising therapeutic strategy to combat resistance to MAPK and RAS inhibitors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-026-03542-7","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T11:53:53Z","timestamp":1784030033000},"page":"1207-1219","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reactivation of DRP1 plays a functional role in resistance to MEK inhibition in pancreatic cancer cells"],"prefix":"10.1038","volume":"135","author":[{"given":"Salma","family":"Sharmin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Kashatus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara J.","family":"Adair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma Bakall","family":"Loewgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0917-3525","authenticated-orcid":false,"given":"Mohammad","family":"Fallahi-Sichani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd W.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8007-0612","authenticated-orcid":false,"given":"David F.","family":"Kashatus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"3542_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/CAAC.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349. https:\/\/doi.org\/10.3322\/CAAC.21820.","journal-title":"CA Cancer J Clin"},{"key":"3542_CR2","unstructured":"Common Cancer Sites \u2014 Cancer Stat Facts [Internet]. [cited 2025 Mar 25]. https:\/\/seer.cancer.gov\/statfacts\/html\/common.html. Accessed (2025)."},{"key":"3542_CR3","doi-asserted-by":"publisher","unstructured":"Witkiewicz AK, McMillan EA, Balaji U, Baek GH, Lin WC, Mansour J, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6. https:\/\/doi.org\/10.1038\/ncomms7744.","DOI":"10.1038\/ncomms7744"},{"key":"3542_CR4","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","volume":"8","author":"ME Bahar","year":"2023","unstructured":"Bahar ME, Kim HJ, Kim DR. Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal Transduct Target Ther. 2023;8:455. https:\/\/doi.org\/10.1038\/s41392-023-01705-z.","journal-title":"Signal Transduct Target Ther"},{"key":"3542_CR5","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature12796","volume":"503","author":"JM Ostrem","year":"2013","unstructured":"Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503:548\u201351. https:\/\/doi.org\/10.1038\/nature12796.","journal-title":"Nature"},{"key":"3542_CR6","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/s41586-024-07205-6","volume":"629","author":"M Holderfield","year":"2024","unstructured":"Holderfield M, Lee BJ, Jiang J, Tomlinson A, Seamon KJ, Mira A, et al. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. Nature. 2024;629:919\u201326. https:\/\/doi.org\/10.1038\/s41586-024-07205-6.","journal-title":"Nature"},{"key":"3542_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.trecan.2024.11.009","volume":"11","author":"T Isermann","year":"2025","unstructured":"Isermann T, Sers C, Der CJ, Papke B. KRAS inhibitors: resistance drivers and combinatorial strategies. Trends Cancer. 2025;11:91\u2013116.","journal-title":"Trends Cancer"},{"key":"3542_CR8","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/nejmoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507\u201316. https:\/\/doi.org\/10.1056\/nejmoa1103782.","journal-title":"N Engl J Med"},{"key":"3542_CR9","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","volume":"386","author":"GV Long","year":"2015","unstructured":"Long GV, Stroyakovskiy D, Gogas H, Levchenko E, De Braud F, Larkin J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386:444\u201351. https:\/\/doi.org\/10.1016\/S0140-6736(15)60898-4.","journal-title":"Lancet"},{"key":"3542_CR10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/nejmoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined Dabrafenib and Trametinib. N Engl J Med. 2015;372:30\u20139. https:\/\/doi.org\/10.1056\/nejmoa1412690.","journal-title":"N Engl J Med"},{"key":"3542_CR11","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1200\/JCO.22.02524","volume":"41","author":"GK Dy","year":"2023","unstructured":"Dy GK, Govindan R, Velcheti V, Falchook GS, Italiano A, Wolf J, et al. Long-term outcomes and molecular correlates of sotorasib efficacy in patients with pretreated KRAS G12C-mutated non-small-cell lung cancer: 2-year analysis of CodeBreaK 100. J Clin Oncol. 2023;41:3311\u20137. https:\/\/doi.org\/10.1200\/JCO.22.02524.","journal-title":"J Clin Oncol"},{"key":"3542_CR12","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1016\/j.ejca.2014.04.024","volume":"50","author":"JR Infante","year":"2014","unstructured":"Infante JR, Somer BG, Park JO, Li CP, Scheulen ME, Kasubhai SM, et al. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. Eur J Cancer. 2014;50:2072\u201381. https:\/\/doi.org\/10.1016\/j.ejca.2014.04.024.","journal-title":"Eur J Cancer"},{"key":"3542_CR13","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/nrm3013","volume":"11","author":"B Westermann","year":"2010","unstructured":"Westermann B. Mitochondrial fusion and fission in cell life and death. Nat Rev Mol Cell Biol. 2010;11:872\u2013884. https:\/\/doi.org\/10.1038\/nrm3013.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3542_CR14","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.molcel.2015.01.002","volume":"57","author":"JA Kashatus","year":"2015","unstructured":"Kashatus JA, Nascimento A, Myers LJ, Sher A, Byrne FL, Hoehn KL, et al. Erk2 phosphorylation of Drp1 promotes mitochondrial fission and MAPK-driven tumor growth. Mol Cell. 2015;57:537\u201351. https:\/\/doi.org\/10.1016\/j.molcel.2015.01.002.","journal-title":"Mol Cell"},{"key":"3542_CR15","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.molcel.2015.01.003","volume":"57","author":"MN Serasinghe","year":"2015","unstructured":"Serasinghe MN, Wieder SY, Renault TT, Elkholi R, Asciolla JJ, Yao JL, et al. Mitochondrial division is requisite to RAS-induced transformation and targeted by oncogenic MAPK pathway inhibitors. Mol Cell. 2015;57:521\u201336. https:\/\/doi.org\/10.1016\/j.molcel.2015.01.003.","journal-title":"Mol Cell"},{"key":"3542_CR16","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.celrep.2019.07.031","volume":"28","author":"S Nagdas","year":"2019","unstructured":"Nagdas S, Kashatus JA, Nascimento A, Hussain SS, Trainor RE, Pollock SR, et al. Drp1 promotes KRas-driven metabolic changes to drive pancreatic tumor growth. Cell Rep. 2019;28:1845\u201359.e5. https:\/\/doi.org\/10.1016\/j.celrep.2019.07.031.","journal-title":"Cell Rep"},{"key":"3542_CR17","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1096\/fj.11-196543","volume":"26","author":"J Rehman","year":"2012","unstructured":"Rehman J, Zhang HJ, Toth PT, Zhang Y, Marsboom G, Hong Z, et al. Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. FASEB J. 2012;26:2175\u201386. https:\/\/doi.org\/10.1096\/fj.11-196543.","journal-title":"FASEB J"},{"key":"3542_CR18","doi-asserted-by":"publisher","first-page":"4814","DOI":"10.1038\/onc.2012.494","volume":"32","author":"J Zhao","year":"2013","unstructured":"Zhao J, Zhang J, Yu M, Xie Y, Huang Y, Wolff DW, et al. Mitochondrial dynamics regulates migration and invasion of breast cancer cells. Oncogene. 2013;32:4814\u201324. https:\/\/doi.org\/10.1038\/onc.2012.494.","journal-title":"Oncogene"},{"key":"3542_CR19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.bbrc.2012.03.118","volume":"421","author":"A Inoue-Yamauchi","year":"2012","unstructured":"Inoue-Yamauchi A, Oda H. Depletion of mitochondrial fission factor DRP1 causes increased apoptosis in human colon cancer cells. Biochem Biophys Res Commun. 2012;421:81\u20135. https:\/\/doi.org\/10.1016\/j.bbrc.2012.03.118.","journal-title":"Biochem Biophys Res Commun"},{"key":"3542_CR20","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nn.3960","volume":"18","author":"Q Xie","year":"2015","unstructured":"Xie Q, Wu Q, Horbinski CM, Flavahan WA, Yang K, Zhou W, et al. Mitochondrial control by DRP1 in brain tumor initiating cells. Nat Neurosci. 2015;18:501\u201310. https:\/\/doi.org\/10.1038\/nn.3960.","journal-title":"Nat Neurosci"},{"key":"3542_CR21","doi-asserted-by":"publisher","first-page":"65001","DOI":"10.18632\/oncotarget.11339","volume":"7","author":"L Zhan","year":"2016","unstructured":"Zhan L, Cao H, Wang G, Lyu Y, Sun X, An J, et al. Drp1-mediated mitochondrial fission promotes cell proliferation through crosstalk of p53 and NF-\u03baB pathways in hepatocellular carcinoma. Oncotarget. 2016;7:65001\u201311. https:\/\/doi.org\/10.18632\/oncotarget.11339.","journal-title":"Oncotarget"},{"key":"3542_CR22","doi-asserted-by":"publisher","first-page":"13254","DOI":"10.18632\/oncotarget.24285","volume":"9","author":"M Peiris-Pag\u00e8s","year":"2018","unstructured":"Peiris-Pag\u00e8s M, Bonuccelli G, Sotgia F, Lisanti MP. Mitochondrial fission as a driver of stemness in tumor cells: mDIVI1 inhibits mitochondrial function, cell migration and cancer stem cell (CSC) signalling. Oncotarget. 2018;9:13254\u201375. https:\/\/doi.org\/10.18632\/oncotarget.24285.","journal-title":"Oncotarget"},{"key":"3542_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31417-x","volume":"13","author":"X Lei","year":"2022","unstructured":"Lei X, Lin H, Wang J, Ou Z, Ruan Y, Sadagopan A, et al. Mitochondrial fission induces immunoescape in solid tumors through decreasing MHC-I surface expression. Nat Commun. 2022;13:3882. https:\/\/doi.org\/10.1038\/s41467-022-31417-x.","journal-title":"Nat Commun"},{"key":"3542_CR24","doi-asserted-by":"publisher","first-page":"7089","DOI":"10.1038\/s41388-019-0949-5","volume":"38","author":"Y Han","year":"2019","unstructured":"Han Y, Kim B, Cho U, Park IS, Kim SI, Dhanasekaran DN, et al. Mitochondrial fission causes cisplatin resistance under hypoxic conditions via ROS in ovarian cancer cells. Oncogene. 2019;38:7089\u2013105. https:\/\/doi.org\/10.1038\/s41388-019-0949-5.","journal-title":"Oncogene"},{"key":"3542_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-1019-6","volume":"9","author":"CY Huang","year":"2018","unstructured":"Huang CY, Chiang SF, Chen WTL, Ke TW, Chen TW, You YS, et al. HMGB1 promotes ERK-mediated mitochondrial Drp1 phosphorylation for chemoresistance through RAGE in colorectal cancer. Cell Death Dis. 2018;9:1004. https:\/\/doi.org\/10.1038\/s41419-018-1019-6.","journal-title":"Cell Death Dis"},{"key":"3542_CR26","doi-asserted-by":"publisher","first-page":"e77065","DOI":"10.1371\/journal.pone.0077065","volume":"8","author":"DM Walters","year":"2013","unstructured":"Walters DM, Stokes JB, Adair SJ, Stelow EB, Borgman CA, Lowrey BT, et al. Clinical, molecular and genetic validation of a murine orthotopic xenograft model of pancreatic adenocarcinoma using fresh human specimens. PLoS ONE. 2013;8:e77065. https:\/\/doi.org\/10.1371\/journal.pone.0077065.","journal-title":"PLoS ONE"},{"key":"3542_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-75899-5","volume":"10","author":"A Rohani","year":"2020","unstructured":"Rohani A, Kashatus JA, Sessions DT, Sharmin S, Kashatus DF. Mito Hacker: a set of tools to enable high-throughput analysis of mitochondrial network morphology. Sci Rep. 2020;10:18941. https:\/\/doi.org\/10.1038\/s41598-020-75899-5.","journal-title":"Sci Rep"},{"key":"3542_CR28","doi-asserted-by":"publisher","first-page":"111818","DOI":"10.1016\/j.celrep.2022.111818","volume":"41","author":"DT Sessions","year":"2022","unstructured":"Sessions DT, Kim KB, Kashatus JA, Churchill N, Park KS, Mayo MW, et al. Opa1 and Drp1 reciprocally regulate cristae morphology, ETC function, and NAD+ regeneration in KRas-mutant lung adenocarcinoma. Cell Rep. 2022;41:111818. https:\/\/doi.org\/10.1016\/j.celrep.2022.111818.","journal-title":"Cell Rep"},{"key":"3542_CR29","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/ncb2310","volume":"13","author":"DF Kashatus","year":"2011","unstructured":"Kashatus DF, Lim KH, Brady DC, Pershing NLK, Cox AD, Counter CM. RALA and RALBP1 regulate mitochondrial fission at mitosis. Nat Cell Biol. 2011;13:1108\u201315. https:\/\/doi.org\/10.1038\/ncb2310.","journal-title":"Nat Cell Biol"},{"key":"3542_CR30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1593\/neo.121712","volume":"15","author":"DM Walters","year":"2013","unstructured":"Walters DM, Lindberg JM, Adair SJ, Newhook TE, Cowan CR, Stokes JB, et al. Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor\/HER2 inhibitor lapatinib. Neoplasia. 2013;15:143\u2013IN10. https:\/\/doi.org\/10.1593\/neo.121712.","journal-title":"Neoplasia"},{"key":"3542_CR31","doi-asserted-by":"publisher","first-page":"28068","DOI":"10.1073\/pnas.2009899117","volume":"117","author":"X Wei","year":"2020","unstructured":"Wei X, Yang J, Adair SJ, Ozturk H, Kuscu C, Lee KY, et al. Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells. Proc Natl Acad Sci USA 2020;117:28068\u201379. https:\/\/doi.org\/10.1073\/pnas.2009899117.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3542_CR32","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/ijc.2910150505","volume":"15","author":"M Lieber","year":"1975","unstructured":"Lieber M, Mazzetta J, Nelson-Rees W, Kaplan M, Todaro G. Establishment of a continuous tumor-cell line (PANC-1) from a human carcinoma of the exocrine pancreas. Int J Cancer. 1975;15:741\u20137. https:\/\/doi.org\/10.1002\/ijc.2910150505.","journal-title":"Int J Cancer"},{"key":"3542_CR33","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.1073\/pnas.87.10.4012","volume":"87","author":"RA Schoumacher","year":"1990","unstructured":"Schoumacher RA, Ram J, Iannuzzi MC, Bradbury NA, Wallace RW, Hon CT, et al. A cystic fibrosis pancreatic adenocarcinoma cell line. Proc Natl Acad Sci USA. 1990;87:4012\u20136. https:\/\/doi.org\/10.1073\/pnas.87.10.4012.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3542_CR34","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1007\/s004280100474","volume":"439","author":"PS Moore","year":"2001","unstructured":"Moore PS, Sipos B, Orlandini S, Sorio C, Real FX, Lemoine NR, et al. Genetic profile of 22 pancreatic carcinoma cell lines. Virchows Arch. 2001;439:798\u2013802. https:\/\/doi.org\/10.1007\/s004280100474.","journal-title":"Virchows Arch"},{"key":"3542_CR35","doi-asserted-by":"publisher","unstructured":"Yu M, Nguyen ND, Huang Y, Lin D, Fujimoto TN, Molkentine JM, et al. Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer. JCI Insight. 2019;4. https:\/\/doi.org\/10.1172\/jci.insight.126915.","DOI":"10.1172\/jci.insight.126915"},{"key":"3542_CR36","doi-asserted-by":"publisher","unstructured":"Silvis MR, Silva D, Rohweder R, Schuman S, Gudipaty S, Truong A, et al. MYC-mediated resistance to trametinib and HCQ in PDAC is overcome by CDK4\/6 and lysosomal inhibition. Journal of Experimental Medicine. 2023;220. https:\/\/doi.org\/10.1084\/jem.20221524.","DOI":"10.1084\/jem.20221524"},{"key":"3542_CR37","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41586-024-07379-z","volume":"629","author":"UN Wasko","year":"2024","unstructured":"Wasko UN, Jiang J, Curiel-Dalton TC, Curiel-Garcia A, Edwards AC, Wang Y, et al. Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinoma. Nature. 2024;629:927\u201336.","journal-title":"Nature"},{"key":"3542_CR38","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1073\/pnas.050586197","volume":"97","author":"H Hermeking","year":"2000","unstructured":"Hermeking H, Rago C, Schuhmacher M, Li Q, Barrett JF, Obaya AJ, et al. Identification of CDK4 as a target of c-MYC. Proc Natl Acad Sci USA 2000;97:2229\u201334. https:\/\/doi.org\/10.1073\/pnas.050586197.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3542_CR39","doi-asserted-by":"publisher","first-page":"31263","DOI":"10.1074\/jbc.M202528200","volume":"277","author":"AJ Obaya","year":"2002","unstructured":"Obaya AJ, Kotenko I, Cole MD, Sedivy JM. The proto-oncogene c-myc acts through the cyclin-dependent kinase (Cdk) inhibitor p27Kip1 to facilitate the activation of Cdk4\/6 and early G1 phase progression. J Biol Chem. 2002;277:31263\u20139. https:\/\/doi.org\/10.1074\/jbc.M202528200.","journal-title":"J Biol Chem"},{"key":"3542_CR40","doi-asserted-by":"publisher","first-page":"4672","DOI":"10.1128\/mcb.19.7.4672","volume":"19","author":"MK Mateyak","year":"1999","unstructured":"Mateyak MK, Obaya AJ, Sedivy JM. c-Myc Regulates Cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points. Mol Cell Biol. 1999;19:4672\u201383. https:\/\/doi.org\/10.1128\/mcb.19.7.4672.","journal-title":"Mol Cell Biol"},{"key":"3542_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-02980-2","volume":"11","author":"W Ji","year":"2020","unstructured":"Ji W, Zhang W, Wang X, Shi Y, Yang F, Xie H, et al. c-myc regulates the sensitivity of breast cancer cells to palbociclib via c-myc\/miR-29b-3p\/CDK6 axis. Cell Death Dis. 2020;11:760. https:\/\/doi.org\/10.1038\/s41419-020-02980-2.","journal-title":"Cell Death Dis"},{"key":"3542_CR42","doi-asserted-by":"publisher","first-page":"11521","DOI":"10.1074\/jbc.M607279200","volume":"282","author":"N Taguchi","year":"2007","unstructured":"Taguchi N, Ishihara N, Jofuku A, Oka T, Mihara K. Mitotic phosphorylation of dynamin-related GTPase Drp1 participates in mitochondrial fission. J Biol Chem. 2007;282:11521\u20139. https:\/\/doi.org\/10.1074\/jbc.M607279200.","journal-title":"J Biol Chem"},{"key":"3542_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-02922-y","volume":"11","author":"R Rong","year":"2020","unstructured":"Rong R, Xia X, Peng H, Li H, You M, Liang Z, et al. Cdk5-mediated Drp1 phosphorylation drives mitochondrial defects and neuronal apoptosis in radiation-induced optic neuropathy. Cell Death Dis. 2020;11:720. https:\/\/doi.org\/10.1038\/s41419-020-02922-y.","journal-title":"Cell Death Dis"},{"key":"3542_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00328-x","volume":"6","author":"DA Farnsworth","year":"2022","unstructured":"Farnsworth DA, Inoue Y, Johnson FD, de Rappard-Yuswack G, Lu D, Shi R, et al. MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression. NPJ Precis Oncol. 2022;6:88. https:\/\/doi.org\/10.1038\/s41698-022-00328-x.","journal-title":"NPJ Precis Oncol"},{"key":"3542_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-020-00251-5","volume":"9","author":"XH Lin","year":"2020","unstructured":"Lin XH, Qiu BQ, Ma M, Zhang R, Hsu SJ, Liu HH, et al. Suppressing DRP1-mediated mitochondrial fission and mitophagy increases mitochondrial apoptosis of hepatocellular carcinoma cells in the setting of hypoxia. Oncogenesis. 2020;9:67. https:\/\/doi.org\/10.1038\/s41389-020-00251-5.","journal-title":"Oncogenesis"},{"key":"3542_CR46","doi-asserted-by":"publisher","first-page":"20988","DOI":"10.18632\/oncotarget.15470","volume":"8","author":"C Zhao","year":"2017","unstructured":"Zhao C, Chen Z, Qi J, Duan S, Huang Z, Zhang C, et al. Drp1-dependent mitophagy protects against cisplatin-induced apoptosis of renal tubular epithelial cells by improving mitochondrial function. Oncotarget. 2017;8:20988\u20131000. https:\/\/doi.org\/10.18632\/oncotarget.15470.","journal-title":"Oncotarget"},{"key":"3542_CR47","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/s41591-019-0368-8","volume":"25","author":"KL Bryant","year":"2019","unstructured":"Bryant KL, Stalnecker CA, Zeitouni D, Klomp JE, Peng S, Tikunov AP, et al. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nat Med. 2019;25:628\u201340. https:\/\/doi.org\/10.1038\/s41591-019-0368-8.","journal-title":"Nat Med"},{"key":"3542_CR48","doi-asserted-by":"publisher","unstructured":"Liu A, Hatch AL, Higgs HN. Effects of phosphorylation on Drp1 activation by its receptors, actin, and cardiolipin. Mol Biol Cell. 2024;35. https:\/\/doi.org\/10.1091\/mbc.E23-11-0427.","DOI":"10.1091\/mbc.E23-11-0427"},{"key":"3542_CR49","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41586-022-05575-3","volume":"613","author":"JL Johnson","year":"2023","unstructured":"Johnson JL, Yaron TM, Huntsman EM, Kerelsky A, Song J, Regev A, et al. An atlas of substrate specificities for the human serine\/threonine kinome. Nature. 2023;613:759\u201366. https:\/\/doi.org\/10.1038\/s41586-022-05575-3.","journal-title":"Nature"},{"key":"3542_CR50","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1182\/blood-2014-02-555292","volume":"124","author":"E Rodr\u00edguez-D\u00edez","year":"2014","unstructured":"Rodr\u00edguez-D\u00edez E, Quereda V, Bellutti F, Prchal-Murphy M, Partida D, Eguren M, et al. Cdk4 and Cdk6 cooperate in counteracting the INK4 family of inhibitors during murine leukemogenesis. Blood. 2014;124:2380\u201390. https:\/\/doi.org\/10.1182\/blood-2014-02-555292.","journal-title":"Blood"},{"key":"3542_CR51","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41392-021-00659-4","volume":"6","author":"S Wang","year":"2021","unstructured":"Wang S, Zheng Y, Yang F, Zhu L, Zhu XQ, Wang ZF, et al. The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives. Signal Transduct Target Ther. 2021;6:249. https:\/\/doi.org\/10.1038\/s41392-021-00659-4.","journal-title":"Signal Transduct Target Ther"},{"key":"3542_CR52","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1158\/1535-7163.MCT-19-1043","volume":"20","author":"BA Willobee","year":"2021","unstructured":"Willobee BA, Gaidarski AA, Dosch AR, Castellanos JA, Dai X, Mehra S, et al. Combined blockade of MEK and CDK4\/6 pathways induces senescence to improve survival in pancreatic ductal adenocarcinoma. Mol Cancer Ther. 2021;20:1246\u201356. https:\/\/doi.org\/10.1158\/1535-7163.MCT-19-1043.","journal-title":"Mol Cancer Ther"},{"key":"3542_CR53","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1158\/0008-5472.CAN-22-0391","volume":"83","author":"CM Goodwin","year":"2023","unstructured":"Goodwin CM, Waters AM, Klomp JE, Javaid S, Bryant KL, Stalnecker CA, et al. Combination therapies with CDK4\/6 inhibitors to treat KRAS-mutant pancreatic cancer. Cancer Res. 2023;83:141\u201357. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-0391.","journal-title":"Cancer Res"},{"key":"3542_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11464-3","volume":"23","author":"H Tang","year":"2023","unstructured":"Tang H, Ge Y, You T, Li X, Wang Y, Cheng Y, et al. A real-world analysis of trametinib in combination with hydroxychloroquine or CDK4\/6 inhibitor as third- or later-line therapy in metastatic pancreatic adenocarcinoma. BMC Cancer. 2023;23:958. https:\/\/doi.org\/10.1186\/s12885-023-11464-3.","journal-title":"BMC Cancer"},{"key":"3542_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41525-022-00346-5","volume":"8","author":"J Shaya","year":"2023","unstructured":"Shaya J, Kato S, Adashek JJ, Patel H, Fanta PT, Botta GP, et al. Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis. NPJ Genom Med. 2023;8:1. https:\/\/doi.org\/10.1038\/s41525-022-00346-5.","journal-title":"NPJ Genom Med"},{"key":"3542_CR56","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1016\/j.celrep.2017.11.022","volume":"21","author":"KR Singleton","year":"2017","unstructured":"Singleton KR, Crawford L, Tsui E, Manchester HE, Maertens O, Liu X, et al. Melanoma therapeutic strategies that select against resistance by exploiting MYC-driven evolutionary convergence. Cell Rep. 2017;21:2796\u2013812. https:\/\/doi.org\/10.1016\/j.celrep.2017.11.022.","journal-title":"Cell Rep"},{"key":"3542_CR57","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/j.ymthe.2022.01.032","volume":"30","author":"D Wang","year":"2022","unstructured":"Wang D, Tian J, Yan Z, Yuan Q, Wu D, Liu X, et al. Mitochondrial fragmentation is crucial for c-Myc-driven hepatoblastoma-like liver tumors. Mol Ther. 2022;30:1645\u201360. https:\/\/doi.org\/10.1016\/j.ymthe.2022.01.032.","journal-title":"Mol Ther"},{"key":"3542_CR58","doi-asserted-by":"publisher","first-page":"MSB167321","DOI":"10.15252\/msb.20167321","volume":"13","author":"M Tarrado-Castellarnau","year":"2017","unstructured":"Tarrado-Castellarnau M, de Atauri P, Tarrag\u00f3-Celada J, Perarnau J, Yuneva M, Thomson TM, et al. De novo MYC addiction as an adaptive response of cancer cells to CDK 4\/6 inhibition. Mol Syst Biol. 2017;13:MSB167321. https:\/\/doi.org\/10.15252\/msb.20167321.","journal-title":"Mol Syst Biol"},{"key":"3542_CR59","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41392-024-02080-z","volume":"10","author":"I Pellarin","year":"2025","unstructured":"Pellarin I, Dall\u2019Acqua A, Favero A, Segatto I, Rossi V, Crestan N, et al. Cyclin-dependent protein kinases and cell cycle regulation in biology and disease. Signal Transduct Target Ther. 2025;10:11. https:\/\/doi.org\/10.1038\/s41392-024-02080-z.","journal-title":"Signal Transduct Target Ther"},{"key":"3542_CR60","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1158\/2159-8290.CD-17-0682","volume":"8","author":"A Hong","year":"2018","unstructured":"Hong A, Moriceau G, Sun L, Lomeli S, Piva M, Damoiseaux R, et al. Exploiting drug addiction mechanisms to select against mapki-resistant melanoma. Cancer Discov. 2018;8:74\u201393. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0682.","journal-title":"Cancer Discov"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03542-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03542-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03542-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:01:38Z","timestamp":1791270098000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03542-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":60,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,10,20]]}},"alternative-id":["3542"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03542-7","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Collection of human PDAC specimens was performed with approval of the Institutional Review Board at the University of Virginia (IRB-HSR # 17238, FWA # 00006183, UVA IRB #00000447) in accordance with all relevant guidelines and regulations in coordination with the Biorepository and Tissue Research Facility. All patients provided written informed consent for participation, and no patients received neoadjuvant therapy. This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Animal Care and Use Committee of the University of Virginia (PHS Assurance #A3245-01).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}